Compare SK Hynix (SKHY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SK Hynix vs Viatris Inc — how do they compare? SK Hynix trades at $191.76 (market cap $945.90B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: SK Hynix is far larger — about 49.5× Viatris Inc's market cap, and Viatris Inc pays a 2.89% dividend while SK Hynix pays none. Which is the better fit depends on your goals.
| SKHY | VTRS | |
|---|---|---|
Market Cap | $945.90B | $19.09B |
Sector | Technology | Health |
52-Week High | $198.63 | $17.86 |
52-Week Low | $126.79 | $9.49 |
Enterprise Value | $896.20B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKHY trades at $185.55, up 4.83% today, with strong fundamental performance including 85.62% net income margin and consistent earnings beats. The stock shows neutral technical signals near pivot point $186, with support at $183 and resistance at $189. Recent news highlights SKHY's leadership in AI memory chips with 50% HBM market share and strong demand from AI infrastructure buildout.
Outlook remains positive with 100% analyst buy ratings and $248 consensus price target representing 34% upside. Key risks include memory cycle volatility and competitive pressures, but strong HBM positioning and expanding AI partnerships provide growth catalysts. Revenue growth accelerated to 85.61% profit margin in 2026 trends.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SK Hynix
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
